News | May 05, 2022
JBCPL emerges as the fastest growing pharma company: Report
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Under this initiative, 700 meals will be provided every day to four hospitals in Mumbai
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
It will be marketed under the brand name Molunamax
The company plans to submit the IND application by the end of 2021
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Subscribe To Our Newsletter & Stay Updated
